指南与共识儿童血液肿瘤与免疫

接受造血细胞移植和免疫效应细胞治疗的儿童体外膜氧合国际多学科共识

Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.
指南 / 共识 · Lancet Child Adolesc Health · 2021-12-09

该国际多学科共识由ELSO、PALISI、EBMT、PTCTC和ESPNIC等组织共同制定,针对接受造血细胞移植(HCT)和免疫效应细胞治疗的儿童使用体外膜氧合(ECMO)的争议性问题提供推荐。这是该患者群体中首个国际多学科共识,旨在为儿科血液科、肿瘤科和重症监护医生提供ECMO候选资格和管理的临床决策支持工具。

要点

  • 接受HCT和免疫效应细胞治疗的儿童使用ECMO存在争议,此前无循证指南。
  • 该共识由五个国际组织共同制定,提供ECMO候选资格和管理的决策支持。
  • 推荐可作为未来ECMO选择标准和研究的基础。

核心结论

  • 该共识为接受HCT和免疫效应细胞治疗的儿童使用ECMO提供了首个国际多学科推荐。

研究设计与样本

  • 由ELSO、PALISI网络(HCT和癌症免疫治疗亚组)、EBMT儿科疾病工作组、PTCTC支持治疗委员会和ESPNIC的POKER组共同制定的共识声明。

主要发现

  • HCT和免疫效应细胞治疗的进展改变了对器官功能障碍可逆性和生存的预期。
  • 该共识提供了针对ECMO候选资格和管理的临床决策支持工具。

临床怎么用

  • 推荐可用于儿科血液科、肿瘤科和重症监护医生在ECMO候选资格和管理决策中。
  • 推荐可作为未来针对ECMO选择标准和床边管理的研究基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Use of extracorporeal membrane oxygenation (ECMO) in children receiving haematopoietic cell transplantation (HCT) and immune effector cell therapy is controversial and evidence-based guidelines have not been established. Remarkable advancements in HCT and immune effector cell therapies have changed expectations around reversibility of organ dysfunction and survival for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (HCT and cancer immunotherapy subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC), and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT and immune effector cell therapy. These are the first international, multidisciplinary consensus-based recommendations on the use of ECMO in this patient population. This Review provides a clinical decision support tool for paediatric haematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations can represent a base for future research studies focused on ECMO selection criteria and bedside management.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Di Nardo M, Ahmad AH, Merli P, et al. Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. Lancet Child Adolesc Health. 2021. PMID: 34895512. doi:10.1016/S2352-4642(21)00336-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。